NeXT Personal®
Molecular Residual Disease (MRD) Detection & Monitoring in Solid Tumors
CommercialActive
Key Facts
Indication
Molecular Residual Disease (MRD) Detection & Monitoring in Solid Tumors
Phase
Commercial
Status
Active
Company
About Personalis
Personalis is transforming cancer management through its advanced genomic sequencing and analysis technologies. The company's core offerings include the NeXT Platform® for comprehensive tumor profiling and the NeXT Personal® assay for highly sensitive MRD detection. Personalis collaborates with leading pharmaceutical companies and research institutions to accelerate drug development and improve patient outcomes. As a publicly traded company, it operates at the intersection of diagnostics, data, and therapeutic development in precision oncology.
View full company profile